The role of tumor suppressor p15Ink4b in the regulation of hematopoietic progenitor cell fate

Blood Cancer Journal

Volumn 3, Issue 1, 2013, Pages

  Humeniuk, R ^a   Rosu Myles, M ^a,b   Fares, J ^a   Koller, R ^a   Bies, J ^a   Wolff, L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HEALTH CANADA   (Canada)

Author keywords

cell fate; differentiation; erythropoiesis; hematopoiesis; p15Ink4b; stem cell

Indexed keywords

ERYTHROPOIETIN RECEPTOR; FLUOROURACIL; MITOGEN ACTIVATED PROTEIN KINASE; PHENYLHYDRAZINE; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR GATA 2; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL COUNT; CELL DIFFERENTIATION; CELL FATE; CELL LINEAGE; GENE EXPRESSION; GENE FUNCTION; GRANULOCYTE; HEMATOPOIETIC CELL; MACROPHAGE; MEGAKARYOCYTE; MOUSE; NONHUMAN; STEM CELL; TUMOR SUPPRESSOR GENE;

EID: 84873679022     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2012.44     Document Type: Article

References (45)

1. Cogle CR, Craig BM, Rollison DE, List AF. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood 2011; 117: 7121-7125.
2. Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ, Baylin SB. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 1997; 57: 837-841.
3. Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 1998; 12: 845-859.
4. Markus J, Garin MT, Bies J, Galili N, Raza A, Thirman MJ et al. Methylation-independent silencing of the tumor suppressor INK4b (p15) by CBFbeta-SMMHC in acute myelogenous leukemia with inv(16). Cancer Res 2007; 67: 992-1000.
5. Tien HF, Tang JH, Tsay W, Liu MC, Lee FY, Wang CH et al. Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol 2001; 112: 148-154.
6. Herman JG, Jen J, Merlo A, Baylin SB. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 1996; 56: 722-727.
7. Lehmann U, Dobbelstein C, Fenner M, Romermann D, Hasemeier B, Metzig K et al. Complete cytogenetic remission after decitabine treatment in a patient with secondary AML harbouring high p15INK4b gene methylation and high global DNA methylation. Ann Hematol 2009; 88: 275-277.
8. Paul TA, Bies J, Small D, Wolff L. Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML. Blood 2010; 115: 3098-3108.
9. Rosu-Myles M, Taylor BJ, Wolff L. Loss of the tumor suppressor p15Ink4b enhances myeloid progenitor formation from common myeloid progenitors. Exp Hematol 2007; 35: 394-406.
10. Bies J, Sramko M, Fares J, Rosu-Myles M, Zhang S, Koller R et al. Myeloid-specific inactivation of p15Ink4b results in monocytosis and predisposition to myeloid leukemia. Blood 2010; 116: 979-987.
11. Wolff L, Garin MT, Koller R, Bies J, Liao W, Malumbres M et al. Hypermethylation of the Ink4b locus in murine myeloid leukemia and increased susceptibility to leukemia in p15(Ink4b)-deficient mice. Oncogene 2003; 22: 9265-9274.
12. Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev 2000; 14: 994-1004.
13. Tsai S, Bartelmez S, Sitnicka E, Collins S. Lymphohematopoietic progenitors immortalized by a retroviral vector harboring a dominant-negative retinoic acid receptor can recapitulate lymphoid, myeloid, and erythroid development. Genes Dev 1994; 8: 2831-2841.
14. Ichikawa Y. Differentiation of a cell line of myeloid leukemia. J Cell Physiol 1969; 74: 223-234.
15. Sun-Hoffman L, Aurigemma RE, Sun B, Ruscetti SK. Transactivation of the GATA-1 promoter by a myb-ets-containing mouse retrovirus is mediated by CACCC elements. Oncogene 1996; 13: 1037-1042.
16. Nishigaki K, Hanson C, Thompson D, Yugawa T, Ruscetti S. Activation of the Jun N-terminal kinase pathway by friend spleen focus-forming virus and its role in the growth and survival of friend virus-induced erythroleukemia cells. J Virol 2005; 79: 12752-12762.
17. Wolff L, Tambourin P, Ruscetti S. Induction of the autonomous stage of transformation in erythroid cells infected with SFFV: helper virus is not required. Virology 1986; 152: 272-276.
18. Banaszynski LA, Chen LC, Maynard-Smith LA, Ooi AG, Wandless TJ. A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. Cell 2006; 126: 995-1004.
19. Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003; 17: 3029-3035.
20. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 2000; 404: 193-197.
21. Darzynkiewicz Z, Li X, Bedner E. Use of flow and laser-scanning cytometry in analysis of cell death. Methods Cell Biol 2001; 66: 69-109.
22. Humeniuk R, Mishra PJ, Bertino JR, Banerjee D. Epigenetic reversal of acquired resistance to 5-fluorouracil treatment. Mol Cancer Ther 2009; 8: 1045-1054.
23. Rosu-Myles M, Wolff L. p15Ink4b: dual function in myelopoiesis and inactivation in myeloid disease. Blood Cells Mol Dis 2008; 40: 406-409.
24. Zhang J, Socolovsky M, Gross AW, Lodish HF. Role of Ras signaling in erythroid differentiation of mouse fetal liver cells: functional analysis by a flow cytometrybased novel culture system. Blood 2003; 102: 3938-3946.
25. Lenox LE, Perry JM, Paulson RF. BMP4 and Madh5 regulate the erythroid response to acute anemia. Blood 2005; 105: 2741-2748.
26. Ye ZJ, Kluger Y, Lian Z, Weissman SM. Two types of precursor cells in a multipotential hematopoietic cell line. Proc Natl Acad Sci USA 2005; 102: 18461-18466.
27. Chang HH, Hemberg M, Barahona M, Ingber DE, Huang S. Transcriptome-wide noise controls lineage choice in mammalian progenitor cells. Nature 2008; 453: 544-547.
28. Walkley CR, Sankaran VG, Orkin SH. Rb and hematopoiesis: stem cells to anemia. Cell Div 2008; 3: 13.
29. Daria D, Filippi MD, Knudsen ES, Faccio R, Li Z, Kalfa T et al. The retinoblastoma tumor suppressor is a critical intrinsic regulator for hematopoietic stem and progenitor cells under stress. Blood 2008; 111: 1894-1902.
30. Chin K, Oda N, Shen K, Noguchi CT. Regulation of transcription of the human erythropoietin receptor gene by proteins binding to GATA-1 and Sp1 motifs. Nucleic Acids Res 1995; 23: 3041-3049.
31. Guillard C, Chretien S, Pelus AS, Porteu F, Muller O, Mayeux P et al. Activation of the mitogen-activated protein kinases Erk1/2 by erythropoietin receptor via a G(i) protein beta gamma-subunit-initiated pathway. J Biol Chem 2003; 278: 11050-11056.
32. Geest CR, Coffer PJ. MAPK signaling pathways in the regulation of hematopoiesis. J Leukoc Biol 2009; 86: 237-250.
33. Geest CR, Buitenhuis M, Groot Koerkamp MJ, Holstege FC, Vellenga E, Coffer PJ. Tight control of MEK-ERK activation is essential in regulating proliferation, survival, and cytokine production of CD34+-derived neutrophil progenitors. Blood 2009; 114: 3402-3412.
34. Cantor AB, Orkin SH. Transcriptional regulation of erythropoiesis: an affair involving multiple partners. Oncogene 2002; 21: 3368-3376.
35. Burda P, Laslo P, Stopka T. The role of PU.1 and GATA-1 transcription factors during normal and leukemogenic hematopoiesis. Leukemia 2010; 24: 1249-1257.
36. Fares J, Koller R, Humeniuk R, Wolff L, Bies J. The tumor suppressor p15Ink4b regulates the differentiation and maturation of conventional dendritic cells. Blood 2012; 119: 5005-5015.
37. Bresnick EH, Lee HY, Fujiwara T, Johnson KD, Keles S. GATA switches as developmental drivers. J Biol Chem 2010; 285: 31087-31093.
38. Bresnick EH, Martowicz ML, Pal S, Johnson KD. Developmental control via GATA factor interplay at chromatin domains. J Cell Physiol 2005; 205: 1-9.
39. Vicente C, Vazquez I, Conchillo A, Garcia-Sanchez MA, Marcotegui N, Fuster O et al. Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities. Leukemia 2011; 26: 550-554.
40. Shimamoto T, Ohyashiki JH, Ohyashiki K. Methylation of p15(INK4b) and E-cadherin genes is independently correlated with poor prognosis in acute myeloid leukemia. Leuk Res 2005; 29: 653-659.
41. Hahn CN, Chong CE, Carmichael CL, Wilkins EJ, Brautigan PJ, Li XC et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet 2011; 43: 1012-1017.
42. Krimpenfort P, Ijpenberg A, Song JY, van der Valk M, Nawijn M, Zevenhoven J et al. p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. Nature 2007; 448: 943-946.
43. Peters G. Cell cycle. Stifled by inhibitions. Nature 1994; 371: 204-205.
44. Dirlam A, Spike BT, Macleod KF. Deregulated E2f-2 underlies cell cycle and maturation defects in retinoblastoma null erythroblasts. Mol Cell Biol 2007; 27: 8713-8728.
45. Choi BY, Choi HS, Ko K, Cho YY, Zhu F, Kang BS et al. The tumor suppressor p16(INK4a) prevents cell transformation through inhibition of c-Jun phosphorylation and AP-1 activity. Nat Struct Mol Biol 2005; 12: 699-707.